Biocon on Q3 earnings performance
- 5 years ago
Biosimilars business is a very capital intensive and investment intensive in terms of R&D and we will need to raise capital either through private equity or IPO, said Kiran Mazumdar Shaw, Chairperson & MD, Biocon.